Genprex Stock (NASDAQ:GNPX)

Revenue Ownership Financials Chart

Previous Close

$0.27

52W Range

$0.20 - $3.97

50D Avg

$0.28

200D Avg

$0.64

Market Cap

$8.78M

Avg Vol (3M)

$2.20M

Beta

-0.48

Div Yield

-

GNPX Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

Mar 29, 2018

Website

GNPX Performance

GNPX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-31.08M	$-23.83M
Net Income	$-21.39B	$-30.86M	$-29.46M
EBITDA	-	$-31.06M	$-23.81M
Basic EPS	$-5.34K	$-22.58	$-24.59
Diluted EPS	$-5.34K	$-22.56	$-24.58

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
DARE	Daré Bioscience, Inc.
AYTU	Aytu BioPharma, Inc.
CRDF	Cardiff Oncology, Inc.
CODX	Co-Diagnostics, Inc.
COCP	Cocrystal Pharma, Inc.
PDSB	PDS Biotechnology Corporation
RVPH	Reviva Pharmaceuticals Holdings, Inc.